Lilly Commits 780,000 Additional Vials of Insulin to Life for a Child
Eli Lilly and Company has committed another 780,000 vials of insulin to the International Diabetes Federation's Life for a Child program. Life for a Child provides free, life-saving medicine to children living in impoverished communities who otherwise would not have access to the insulin they need. The International Diabetes Federation (IDF) is the global advocate for people with diabetes, representing 230 national diabetes associations in 170 countries and territories.
Lilly's new commitment builds on the company's previous donation of 800,000 vials of insulin over the past 6 years, which reached more than 14,000 children in 34 countries. During the next 3 years, Lilly will donate approximately 260,000 vials of insulin each year to the Life for a Child program. This commitment will allow Life for a Child to continue providing treatment for children in the countries where the program currently operates and to increase the amount of insulin supplied for distribution.
Lilly is the sole provider of insulin to the IDF's Life for a Child program. The original donation of 800,000 vials represented Lilly's largest-ever product donation at the time. This new development extends Lilly's total commitment to Life for a Child to nearly 1.6 million vials of insulins.
"We know that a diagnosis of diabetes is a monumental event for any child and family. But, sadly, in many lower- and middle-income countries, that diagnosis all too often means no future at all," said Graham Ogle, Life for a Child general manager. "Lilly's donation of insulin offers continued hope to children and families in need who are trying to manage type 1 diabetes in very challenging conditions."
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance